Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
CNBC
Sat, 05/19/18 - 11:30 am
Tags:
migraines, Amgen, Novartis, Aimovig
AstraZeneca drops Amgen-partnered solid tumor drug
Fierce Biotech
Fri, 05/18/18 - 09:37 pm
Tags:
AstraZeneca, MEDI-565, solid tumors, Amgen
Amgen’s new migraine drug will cost 30 percent less than Wall Street expected
Stat
Thu, 05/17/18 - 09:48 pm
Tags:
Amgen, Novartis, migraines, Aimovig, drug pricing
Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?
Fierce Pharma
Thu, 05/17/18 - 09:42 pm
Tags:
Amgen, Novartis, Aimovig, FDA, migraines
Pfizer’s Epoetin Alfa Biosimilar Approved by FDA
RAPS.org
Tue, 05/15/18 - 09:13 pm
Tags:
FDA, Amgen, biosimilars, Epogen, epoetin alfa, Retacrit, Pfizer
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
Sun, 05/6/18 - 01:33 pm
Tags:
PCSK9 inhibitors, Sanofi, Regeneron, Amgen, Praluent, Repatha
Amgen focuses on migraine launch as growth remains slow
Biopharma Dive
Wed, 04/25/18 - 10:54 pm
Tags:
Amgen, earnings, Repatha, Kyprolis, Prolia, Xgeva
Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
Reuters
Tue, 04/24/18 - 10:47 pm
Tags:
Express Scripts, migraines, PBMs, Amgen, Eli Lilly
Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Xtalks
Fri, 04/6/18 - 11:26 am
Tags:
Amgen, Repatha, outcome-based pricing, drug pricing, patients
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
Biopharma Dive
Wed, 04/4/18 - 10:12 pm
Tags:
Amgen, Repatha
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Fierce Pharma
Wed, 04/4/18 - 09:03 am
Tags:
Amgen, Repatha, DTC ads, heart attack, stroke
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
RAPS.org
Tue, 04/3/18 - 11:04 pm
Tags:
Amgen, Blincyto, ALL, B-cell precursor ALL
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Investors Business Daily
Fri, 03/30/18 - 09:26 am
Tags:
Novartis, Amgen, Enbrel, biosimilars
Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing
Fierce Pharma
Tue, 03/27/18 - 10:00 pm
Tags:
AbbVie, Eli Lilly, Amgen, executive pay, drug pricing
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Xtalks
Mon, 03/26/18 - 09:36 am
Tags:
Amgen, Allergan, Herceptin, biosimilars, ABP 980, CHMP, EMA, Roche
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
Tags:
drug launches, Hemlibra, Roche, Biktarvy, Gilead Sciences, Ozempic, Novo Nordisk, Erleada, JNJ, Shingrix, GSK, Patisiran, Alnylam, Sanofi, Epidiolex, GW Pharma, Aimovig, Amgen, Novartis, lanadelumab, Shire, Elagolix, AbbVie, Steglatro, Pfizer, Merck, Sublocade, Indivior
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Investors Business Daily
Mon, 03/19/18 - 12:07 pm
Tags:
Amgen, Celgene, M&A, Alexion, AstraZeneca
Drug companies are beginning to wake up to this new risk factor
Marketwatch
Mon, 03/19/18 - 12:05 pm
Tags:
pharma industry, co-pay coupons, Pfizer, Sanofi, Amgen, Novartis
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Tue, 03/13/18 - 09:30 pm
Tags:
Amgen, Repatha, Sensipar, generics, Sanofi, Regeneron, Praluent
Top 5 boards for week ending March 10, 2018
CP Wire
Sun, 03/11/18 - 03:05 pm
Tags:
Daiichi Sankyo, Shire, Amgen, Sanofi, AstraZeneca

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.